Luna LifeSci Advisors
Luna LifeSci Advisors consults across the NAMs ecosystem, helping MPS developers grow and scale novel platforms, and guiding pharma and CROs to evaluate, adopt, and integrate MPS technologies into preclinical workflows. Our 25+ years of expertise spans strategy, technology development, platform validation, workflow integration, regulatory alignment, fundraising, company building, and commercial execution.
Frontier Bio Corporation
Frontier Bio creates bioprinted 3D human models (BBB, lung, vasculature) to improve clinical translation and reduce reliance on animal testing.
Nagi Bioscience
We are a Swiss high-tech company developing and offering cutting-edge biological testing solutions that enable scientists to generate insights they need to fuel life-changing discoveries in a faster, more efficient, and ethical way. Our technologies are designed to integrate seamlessly into existing lab environments, enhancing efficiency, accuracy, and reproducibility.
Microtissues, Inc.
Since 2010, Microtissues, Inc has been selling the 3D PetriDish, a reusable micro-mold platform system for forming multi-cellular spheroids and organoids from primary cells, cancer cells, stem cells and cell lines. Our products are distributed worldwide by Millipore Sigma and have been used in over 200 peer-reviewed publications, a list which is available on our website.
Bioprinting Laboratories
Bioprinting Labs’ pillar/perfusion plates enable robust and reproducible organoid culture and in situ analysis. Our products streamline organoid-based assays by facilitating miniature organoid culture and enhancing organoid maturity through dynamic culture in the pillar/perfusion plates.
Exir Bio
Exir Bio’s goal is to accelerate drug discovery, efficacy, and safety assessments by combining nonhuman primate (NHP) in vitro / in vivo models,
replacing, reducing, and refining (3R’s) the use of NHPs – necessary due to the global shortage of NHPs and in accordance with US Modernization Act
2.0.
Exir Bio has access to ~20,000 NHP’s / 8 species across several colonies in the US, all with known origin and bred in captivity per FDA and European
Union requirements.
MEPSGEN
MEPSGEN delivers an automated MPS ecosystem designed to bridge the gap between in vitro assays and human clinical outcomes. Combining modular MEPS-X chips with the ProMEPS™ automated tissue-culture platform, MEPSGEN enables standardized, reproducible human tissue models for robust efficacy and toxicity assessment, supporting more predictive and decision-ready preclinical research.
Ncardia
For more than a decade, Ncardia has been pioneering innovations in human induced pluripotent stem cells (iPSC).
Emulate
Emulate develops a breadth of Organ-Chip models with a focus on recreating the microenvironment and mechanical forces cells experience in vivo. Hardware automating media flow and stretch, Bio-Kits including chips and qualified human cells, and a range of standard and custom services are available.